Less Ads, More Data, More Tools Register for FREE

Pin to quick picksWilmington Regulatory News (WIL)

Share Price Information for Wilmington (WIL)

Share Price is delayed by 15 minutes
Get Live Data
257.00    -3.00 (-1.15%)
Bid:
252.00
Ask:
257.00
Spread: 5.00 (1.984%)
Market Cap: £230.16m
WIL Live PriceLast checked at - London Stock Exchange

Intraday Wilmington Share Chart

Acquisition

19 Jan 2016 07:00

RNS Number : 2460M
Wilmington PLC
19 January 2016
Β 

Β 

19 January 2016

Wilmington plc

Β 

Acquisition of JMH Publishing Limited trading as "Wellards"

Β 

Β· Acquisition adds online education capability for the Insight knowledge areaΒ 

Β 

Β· Wellards extensive NHS knowledge base strengthens Wilmington's Healthcare offering

Β 

Β· High quality revenue streams - 70% from subscription products with over 90% renewal rates

Β 

Wilmington plc ("Wilmington" or "the Group"), the knowledge leader in Risk & Compliance, Finance, Legal, and Insight, announces the acquisition of JMH Publishing Ltd ("Wellards" or "the business"), a leading UK provider of specialist and accredited online education for the healthcare industry and owner of the respected trading brand "Wellards".

Β 

As part of Wilmington, Wellards will become the principal education and training platform for the Insight division and will benefit from Wilmington's enhanced healthcare market access, both in the UK and in mainland Europe.

Β 

Terms of the deal

Β 

Wilmington is acquiring Wellards for an initial consideration of Β£4.2m payable in cash. Wellards is being acquired with Β£1.3m of cash in its balance sheet. A final payment of up to Β£0.9m in March 2016 will be made once the final net current asset position has been agreed.

Β 

The consideration will be financed out of the Group's existing Β£65.0m multicurrency debt facility and is expected to be earnings enhancing in the first full year of ownership.

Β 

Background to Wellards

Β 

Wellards, established in 1990 is based in Kent, England and is managed by its founder John Heath, CEO who will remain with the business for a transitional period of one year. Wellards core online modules deliver the industry standard for effective and comprehensive NHS training and are an indispensable resource to enable understanding of the NHS and how it functions.

Β 

Wellards runs over 70 online courses and has more than 25,000 registered users. Subjects covered include critical areas for pharma industry representatives such as market access and financial flows, clinical modules of key therapy areas such as cancer, diabetes and cardiovascular health, ABPI code and compliance. Over 70% of its revenue is generated by its online training portal, Wellards Academy, which services the needs of UK pharmaceutical and Medtech commercial staff.

Β 

In the twelve month period ended 31 October 20151, revenue per the unaudited management accounts was Β£2.0m, an increase of 12 percent on the same period in 2014 and the adjusted profit before interest, amortisation and taxation was Β£0.6m1. Gross assets were 2.0m1. Wellards will provide Wilmington with an additional attractive recurring revenue stream as over 70% of its revenue is subscription based with over 90% renewal rates.

Β 

Acquisition rationale

Β 

The acquisition of Wellards is consistent with Wilmington's strategy of acquiring complementary businesses with high repeat revenues and strong, cash generative income streams in the Group's key markets. The addition of Wellards provides Wilmington with education capability for its Insight division completing the strategic objective of having information, networking and education offerings across all of Wilmington's four knowledge areas.

Β 

1 unaudited.

Β 

Commenting on the acquisition, Pedro Ros, Chief Executive Officer of Wilmington, said:

Β 

"I am delighted to welcome Wellards to Wilmington; its addition completes one of our strategic objectives of having information, education and networking capabilities for each of our knowledge areas. I am particularly excited by the scalability of the online products both in the broader healthcare industry and internationally where we can utilise our existing market access in particular to the French and German healthcare markets."

Β 

John Heath, founder and CEO of Wellards commented:Β 

Β 

"I'm delighted that Wellards is now part of Wilmington. For many years we have worked closely with Binleys; a business within Wilmington's Insight division, providing customers with the knowledge and insight needed to interpret the practical value of the Binleys resource and this acquisition is a very natural extension of our partnership.

Β 

I'm looking forward to developing new services which will enhance the product portfolio of both companies"

Β 

For further information, please contact:

Wilmington plc

Pedro Ros, Chief Executive Officer

Tony Foye, Chief Financial Officer

020 7422 6800

FTI Consulting

Charles Palmer

Emma Appleton

020 3727 1000

Β 

Notes to Editors

Β 

Wilmington plc is the recognised knowledge leader and partner of choice for information, education and networking in Risk & Compliance, Finance and Legal as well as the Insight leader in a number of chosen industries. Capitalised at approximately Β£225 million, Wilmington floated on the London Stock Exchange in 1995.

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
ACQFVLLFQFFBBBF
Date   Source Headline
17th Apr 202611:20 amRNSHolding(s) in Company
15th Apr 20263:56 pmRNSBoard changes
15th Apr 202611:21 amRNSSave As You Earn Options
11th Mar 202611:00 amRNSDirector Declaration
11th Mar 202611:00 amRNSDirector Declaration
26th Feb 20267:00 amRNSHalf-year Financial Report
11th Feb 20262:44 pmRNSNotice of half year-end results
21st Jan 202611:19 amRNSNotice of Half Year Results
23rd Dec 20257:00 amRNSAppointment of Joint Corporate Broker
23rd Dec 20257:00 amRNSAppointment of Joint Corporate Broker
5th Dec 20259:56 amRNSAcquisition of Conversia completed
28th Nov 20254:23 pmRNSDirector/PDMR Shareholding
28th Nov 202511:22 amRNSAcquisition of Conversia cleared to complete
25th Nov 20259:19 amRNSResult of AGM
10th Nov 20255:54 pmRNSDirectorate change
1st Oct 20252:51 pmRNSDirector/PDMR Shareholding
1st Oct 20252:49 pmRNSDirector/PDMR Shareholding
1st Oct 20257:00 amRNSDirector/PDMR Shareholding
1st Oct 20257:00 amRNSTotal Voting Rights
22nd Sep 202512:48 pmRNSDirector/PDMR Shareholding- Replacement
22nd Sep 202511:52 amRNSDirector/PDMR Shareholding
22nd Sep 20257:00 amRNSFinancial results for the year ended 30 June 2025
5th Sep 202510:58 amRNSHolding(s) in Company
1st Sep 20257:00 amRNSNotice of year-end results
29th Aug 202511:07 amRNSHolding(s) in Company
12th Aug 20257:03 amRNSProposed acquisition of Conversia
12th Aug 20257:00 amRNSDirector Declaration
1st Aug 20257:00 amRNSAppointment of Joint Corporate Broker
30th Jul 20257:00 amRNSStatement in relation to a potential acquisition
23rd Jul 20257:00 amRNSTrading Statement
1st Jul 20257:00 amRNSTotal Voting Rights
26th Jun 20259:00 amRNSDirector/PDMR Shareholding
13th Jun 20257:00 amRNSTransaction in Own Shares
12th Jun 20257:00 amRNSTransaction in Own Shares
11th Jun 20257:00 amRNSTransaction in Own Shares
9th Jun 20257:00 amRNSTransaction in Own Shares
6th Jun 20257:00 amRNSTransaction in Own Shares
5th Jun 20257:00 amRNSTransaction in Own Shares
4th Jun 20257:00 amRNSTransaction in Own Shares
3rd Jun 20257:00 amRNSTransaction in Own Shares
2nd Jun 20259:30 amRNSTotal Voting Rights
2nd Jun 20257:00 amRNSTransaction in Own Shares
30th May 20257:00 amRNSTransaction in Own Shares
29th May 20257:00 amRNSTransaction in Own Shares
28th May 20257:00 amRNSTransaction in Own Shares
27th May 20257:00 amRNSTransaction in Own Shares
23rd May 20257:00 amRNSTransaction in Own Shares
22nd May 20257:00 amRNSTransaction in Own Shares
21st May 20257:00 amRNSTransaction in Own Shares
20th May 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.